Last updated: April 25, 2026
Who Supplies Aplenzin (bupropion hydrobromide) in the US?
Aplenzin is a branded formulation of bupropion hydrobromide. In the US, the supply chain is organized around (1) the labeler/manufacturer of the finished product and (2) authorized distributors used to move the product into retail, hospital, and channel accounts. Because “supplier” can mean either finished-product manufacturer or component sourcing, the most investable and auditable answers start with the FDA labeler/manufacturer information and the controlled distribution network used for US commerce.
What is Aplenzin’s finished-product labeler?
Aplenzin is marketed as bupropion hydrobromide extended-release tablets. The FDA label for Aplenzin identifies the manufacturer of the finished dosage form and the labeler responsible for regulatory submission.
| Item |
US product definition |
Primary relevance |
| Brand |
Aplenzin |
Branded finished drug product |
| API (active ingredient) |
Bupropion hydrobromide |
Determines API suppliers and filings |
| Dosage form |
Extended-release tablets |
Locks in formulation and manufacturing scale needs |
| Regulatory anchor |
FDA labeler/manufacturer on prescribing information |
Identifies finished-product supplier for the US market |
Bottom line: the “supplier” that matters for commercialization risk and substitution is the finished-product manufacturer/labeler named on the FDA prescribing information.
Who are the suppliers: finished-product manufacturers or API makers?
Pharmaceutical “supplier” questions typically split into two sourcing layers:
- Finished-product supplier (labeler/manufacturer): supplies Aplenzin tablets into the US distribution chain. This is the entity you track for launch continuity, supply interruptions, and lot availability.
- API supplier (bupropion hydrobromide): supplies the raw API into the formulation sites. This matters for chemical sourcing risk and for understanding upstream patent landscape and facility constraints.
For Aplenzin, the practical, channel-facing supplier is the finished-product labeler/manufacturer. Upstream API suppliers are generally identified via supplier disclosures in regulatory filings and third-party databases, but those can vary by year and by geography.
How to identify the actual US distribution suppliers for Aplenzin?
US distribution for a branded prescription product typically runs through:
- Primary wholesalers (national distribution networks)
- GPO and hospital distribution partners
- Authorized distributors aligned to the finished-product labeler’s supply chain
These parties are not “API suppliers.” They are commercial intermediaries that can be critical for:
- channel inventory levels
- tender availability to hospitals
- “in-stock” status at retail chains
In practice, to map Aplenzin’s “suppliers” for buying power and logistics, you track:
- the FDA labeler/manufacturer (finished product origin)
- the wholesaler/distributor listing in channel catalogs used by your procurement team
- lot-level data in the pharmacy/hospital ordering system (where available)
What sourcing risks apply to Aplenzin’s supplier structure?
Aplenzin’s risk profile is driven by whether disruptions occur at:
- API manufacturing capacity (bupropion hydrobromide)
- finished-dose manufacturing (tablet manufacturing and release)
- packaging and labeling steps (labeling lot compliance)
- distribution continuity (wholesaler inventories)
For an investor or R&D operator, the two key questions are:
- Is supply constrained by API availability or by finished-dose manufacturing slots?
- Do supply interruptions map to a specific labeler site or to broader upstream issues?
Are there multiple suppliers for Aplenzin?
Branded products can have multiple supply realities:
- Multiple finished-dose production sites controlled by the same labeler
- Multiple API production sources meeting qualification and specifications
- Variable distribution partners by contract term
The legally anchored starting point remains the FDA labeler/manufacturer and the authorized distribution channel used in US commerce.
Key Takeaways
- For Aplenzin, the primary “supplier” in commercial terms is the finished-product labeler/manufacturer named on the FDA prescribing information.
- “Supplier” can mean API maker or finished-dose labeler; the most actionable supply chain view starts with the finished-product manufacturer and then maps upstream API risk by qualification and sourcing continuity.
- Distribution continuity in the US is typically routed through primary wholesalers and authorized distribution partners, not direct-to-channel API sourcing.
FAQs
1) Is Aplenzin supplied by an API manufacturer directly to pharmacies?
No. Pharmacies and hospital systems typically source Aplenzin as finished product through authorized distribution/wholesaler channels tied to the FDA labeler/manufacturer.
2) What is the active ingredient in Aplenzin that determines upstream API sourcing?
Aplenzin’s active ingredient is bupropion hydrobromide.
3) Does “supplier” for Aplenzin refer to API makers or the finished-dose manufacturer?
It can refer to either, but the finished-dose manufacturer/labeler is the most direct supplier for US channel availability and supply risk.
4) Why can Aplenzin have different upstream API sources over time?
API sourcing can change by qualification status, capacity, and contractual supply while still meeting the product’s API specifications.
5) How do I track Aplenzin supply chain continuity for procurement or investment diligence?
Start with the FDA labeler/manufacturer for the finished product, then confirm channel delivery through the authorized wholesale/distributor network and lot-level availability in your ordering systems.
References
[1] U.S. Food and Drug Administration. Prescribing Information for Aplenzin (bupropion hydrobromide extended-release tablets).
